Major TOI holder Jorey Chernett adds 50,000 Oncology Institute shares

Rhea-AI Filing Summary

Oncology Institute, Inc. disclosed that major shareholder Jorey Chernett, a more than ten percent owner, made an open-market purchase of 50,000 shares of common stock. The shares were bought at a weighted average price of $3.15 per share, with individual trade prices ranging from $3.11 to $3.19. Following this transaction, Chernett directly owns 10,451,929 shares of Oncology Institute common stock, indicating this buy added modestly to an already large position.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chernett Jorey

(Last) (First) (Middle)

6222 INDIANWOOD TR.

(Street)

BLOOMFIELD HILLS MICHIGAN 48301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Oncology Institute, Inc. [ TOI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/26/2026		P		50,000	A	$3.15(1)	10,451,929	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price, rounded to the nearest cent. These shares were purchased in multiple transactions at prices ranging from $3.11 to $3.19, rounded to the nearest cent, inclusive. Mr. Chernett undertakes to provide the Issuer and any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price such shares were purchased.

	/s/ Jorey Chernett	03/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Oncology Institute (TOI) report for Jorey Chernett?

Oncology Institute reported that major shareholder Jorey Chernett bought 50,000 common shares. The transaction was an open-market purchase, increasing his direct holdings to 10,451,929 shares, signaling a small incremental addition to an already substantial ownership stake.

At what prices did Jorey Chernett buy Oncology Institute (TOI) shares?

Chernett’s 50,000 Oncology Institute shares were purchased at a weighted average price of $3.15. According to the disclosure, the individual trades occurred at prices ranging from $3.11 to $3.19 per share, rounded to the nearest cent.

How many Oncology Institute (TOI) shares does Jorey Chernett own after this Form 4?

After the reported purchase, Jorey Chernett directly owns 10,451,929 Oncology Institute shares. This reflects his position as a more than ten percent beneficial owner, with the new 50,000-share buy modestly increasing his overall stake.

Was the Oncology Institute (TOI) insider transaction an open-market buy or another type?

The transaction was an open-market purchase of common stock. The Form 4 identifies it with code P, described as a purchase in the open market or private transaction, rather than a grant, option exercise, or tax-related disposition.

Does the Form 4 for Oncology Institute (TOI) mention any trading plan for this purchase?

The disclosure describes pricing details but does not reference a Rule 10b5-1 trading plan. It notes the trades were executed across multiple prices and offers to provide full breakdowns to the issuer, security holders, or SEC staff upon request.